
    sponsor decision to analyze available safety and efficacy data
  
['obesity', 'type 2 diabetes']
['zgn-440 for injectable suspension', 'zgn-440 placebo for injectable suspension']

        Inclusion Criteria:

          -  Obese with BMI ≥30 kg/m2

          -  Type 2 diabetes mellitus

          -  HbA1c of 7-11%

          -  Fasting glucose <15.5 mmol/L

          -  Treated with diet and exercise alone or with a stable regimen of metformin,
             sulfonylurea, pioglitazone, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT-2 inhibitor
             or any combination of these agents

          -  Female subjects must be surgically sterile, post-menopausal or using long-acting
             contraception, which includes intrauterine devices or use of an implanted or
             injectable contraceptive

        Exclusion Criteria:

          -  Current or recent use of insulin

          -  Severe hypoglycemia within the prior 6 months

          -  Metabolic disorders or genetic disorders linked to obesity (e.g., Prader-Willi
             Syndrome)
      